Trial results

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

NCT07724340 on ClinicalTrials.gov · last registry update 2026-09-29

Closed to new participants; the 150 already enrolled are still being followed. Due to report February 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Antag Therapeutics

Sponsor type

Industry

Enrollment

150

Started

2026-06-19

Primary completion

2027-02 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Body weight

Conditions studied

Adults With Overweight/Obesity and Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.